Tarveda Therapeutics scores $38 mln Series C

By Iris Dorbian — 2 weeks ago

Tarveda Therapeutics (formerly known as Blend Therapeutics) has raised $38 million in Series C funding. Novo A/S and return backer New Enterprise Associates led the round. The other investors included Flagship Ventures, NanoDimension and Eminent Venture Capital. In conjunction with the financing, Nilesh Kumar of Novo Ventures (US) Inc. and Dr. Frank Torti of NEA have been added to Tarveda’s board of directors while Drew Fromkin has been appointed interim board chairman.Watertown, Massachusetts-based Tarveda is a biopharmaceutical company focused on treating patients with solid tumor cancers.

Continue

Flagship Ventures-backed Joule and Red Rock Biofuels to merge

By Iris Dorbian — 3 months ago

Joule and Red Rock Biofuels, both of which are backed by Flagship Ventures, have agreed to merge. No financial terms were disclosed. Also, Dr. Brian Baynes, a partner at Flagship Ventures who is currently on the board of both Joule and Red Rock, will become president and CEO of the combined companies. Bedford, Massachusetts-based Joule is an alternative fuel developer while Red Rock Biofuels, which is located in Fort Collins, Colorado, is a provider of renewable biofuels.

Continue

TARIS Biomedical scores $32 mln

By Iris Dorbian — 4 months ago

TARIS Biomedical, which focuses on developing new treatments for urologic diseases, has secured $32 million in funding. Flagship Ventures led the round with participation from Polaris Venture Partners and RA Capital Management. Also, TARIS has appointed Dr. Christopher Cutie as vice president of clinical development. And, the company has named Kevin Finney, most recently Allergan’s vice president and corporate development head, and Mark Iwicki, most recently president and CEO of Civitas Therapeutics, to its board of directors.

Continue

Pronutria Biosciences pulls in $39 mln Series C

By Iris Dorbian — 9 months ago

Cambridge, Massachusetts-based Pronutria Biosiences, a developer of treatments to mediate amino acid biology, has closed $39 million in Series C funding. Fidelity Management & Research Company led the round with participation from other investors that included Flagship Ventures.

Continue

Denali launches with $217 mln

By Iris Dorbian — 9 months ago

Denali Therapeutics Inc, a developer of treatments for neurodegenerative diseases, has launched with a $217 million investment commitment. The investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund.

Continue

Joule grabs $40 mln

By Iris Dorbian — 9 months ago

Bedford, Massachusetts-based alternative fuel developer Joule has raised $40 million in funding. The investors included Flagship Ventures.

Continue

VC-backed Blend Therapeutics appoints Fromkin as president and CEO

By Iris Dorbian — 10 months ago

Watertown, Massachusetts-based Blend Therapeutics Inc, a biopharmaceutical company focused on treating patients with solid tumor cancers, has named Drew Fromkin as president, CEO and a member of the company’s board of directors. Previously, Fromkin worked at Clinical Data Inc where he served as President and CEO. Blend Therapeutics’ backers include Eminent Venture Capital, Flagship Ventures, NanoDimension and New Enterprise Associates.

Continue

MPM Capital adds new MD to team

By Iris Dorbian — 10 months ago

MPM Capital named Gregory Sieczkiewicz as managing director and chief counsel, intellectual property. The appointment is effective immediately. Previously, Sieczkiewicz worked at Flagship Ventures where he served as vice president of intellectual property.

Continue

Flagship Ventures to back Red Rock Biofuels

By Iris Dorbian — 11 months ago

Flagship Ventures has agreed to invest in Red Rock BioFuels LLC. No financial terms were disclosed. Also, Flagship Ventures will take a seat on Red Rock’s board of directors. Based in Fort Collins, Colorado, Red Rock Biofuels is a provider of renewable biofuels.

Continue

Blend Therapeutics scores $21 mln

By Iris Dorbian — 1 year ago

Watertown, Mass.-based Blend Therapeutics, a biopharmaceutical firm focused on treating cancer, has raised $21 million in funding. Blend’s investors include New Enterprise Associates, Flagship Ventures, NanoDimension and Eminent Venture Capital.

Continue

VC-backed Acceleron Pharma adds to board of directors

By Iris Dorbian — 1 year ago

Acceleron Pharma has appointed Dr. Francois Nader to its board of directors. Nader is president, CEO and a member of the board of directors of NPS Pharma. Acceleron Pharma’s backers include Advanced Technology Ventures, Flagship Ventures, OrbiMed Advisors, Polaris Ventures and Venrock. Based in Cambridge, Mass., Acceleron is focused on developing novel protein therapeutics for cancer and rare diseases.

Continue

Seres Health fetches $48 mln

By Iris Dorbian — 1 year ago

Seres Health has raised $48 million in Series C funding. The investors in this round were not named; however, the firm was seeded by Flagship Ventures. Based in Cambridge, Mass., Seres Health is a biotherapeutic company focused on developing drugs that target the human microbiome.

Continue